Zipsor, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults, received FDA approval in June 2009.
As per the agreement, Ferring’s orthopaedic sales force is expected to promote Zipsor to certain orthopaedic surgeons, rheumatologists, sports medicine physicians and physiatrists in the US. Ferring will receive a royalty on Zipsor sales generated by a pre-defined target prescriber base. Co-promotion efforts will begin on May 3, 2010.
William Garbarini, vice president of orthopaedics / urology business unit at Ferring Pharmaceuticals, said: “Zipsor represents an exciting addition to our current orthopaedic product portfolio. Ferring has successfully commercialised Euflexxa in the US and welcomes the opportunity to expand our offering to the orthopaedic community by helping orthopaedic surgeons and rheumatologists treat patients with acute pain.”
Natasha Giordano, chief operating officer at Xanodyne, said: “We are pleased to partner with a quality company such as Ferring to help us extend the reach of Zipsor in the US beyond pain specialists and other selected physicians who are the primary focus of our current sales efforts. We look forward to working together to leverage the early market success of Zipsor and to reach considerably more practitioners who attend to the needs of patients with acute pain.”